AbbVie Operating Cycle from 2010 to 2026

ABBV Stock  USD 219.26  1.15  0.53%   
AbbVie Operating Cycle yearly trend continues to be fairly stable with very little volatility. Operating Cycle will likely drop to 172.95 in 2026. During the period from 2010 to 2026, AbbVie Operating Cycle regression line of quarterly data had mean square error of  466.63 and geometric mean of  158.59. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
185.18
Current Value
172.95
Quarterly Volatility
20.99971303
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AbbVie financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AbbVie's main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.1 B, Interest Expense of 3.4 B or Selling General Administrative of 7.5 B, as well as many indicators such as Price To Sales Ratio of 3.46, Dividend Yield of 0.0288 or PTB Ratio of 89.34. AbbVie financial statements analysis is a perfect complement when working with AbbVie Valuation or Volatility modules.
  
Build AI portfolio with AbbVie Stock
Check out the analysis of AbbVie Correlation against competitors.

Latest AbbVie's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of AbbVie Inc over the last few years. It is AbbVie's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AbbVie's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Very volatile
   Operating Cycle   
       Timeline  

AbbVie Operating Cycle Regression Statistics

Arithmetic Mean159.80
Geometric Mean158.59
Coefficient Of Variation13.14
Mean Deviation15.89
Median149.83
Standard Deviation21.00
Sample Variance440.99
Range84.7123
R-Value(0.09)
Mean Square Error466.63
R-Squared0.01
Significance0.73
Slope(0.37)
Total Sum of Squares7,056

AbbVie Operating Cycle History

2026 172.95
2025 185.18
2024 161.02
2023 148.24
2022 145.77
2021 130.24
2020 148.82

About AbbVie Financial Statements

AbbVie investors use historical fundamental indicators, such as AbbVie's Operating Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AbbVie. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 185.18  172.95 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.